Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada. more
Time Frame | ZURA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -8.39% | -1.8% | -0.77% |
1-Month Return | -46.82% | -3.48% | 0.71% |
3-Month Return | -28.29% | -7.2% | 8.81% |
6-Month Return | -34.46% | -1.54% | 12.32% |
1-Year Return | -42.43% | 8.39% | 30.57% |
3-Year Return | -69.24% | 6.07% | 29.21% |
Dec '21 | Dec '22 | Dec '23 | ||||
---|---|---|---|---|---|---|
Total Revenue | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Cost of Revenue | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Gross Profit | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Gross Margin | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Operating Expenses | 1.09M | 2.68M | 62.64M | [{"date":"2021-12-31","value":1.74,"profit":true},{"date":"2022-12-31","value":4.27,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Operating Income | (1.09M) | (2.68M) | (62.64M) | [{"date":"2021-12-31","value":-109199000,"profit":false},{"date":"2022-12-31","value":-267514100,"profit":false},{"date":"2023-12-31","value":-6263800000,"profit":false}] | ||
Total Non-Operating Income/Expense | - | (24.66M) | 4.26M | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-578.67,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] | ||
Pre-Tax Income | 8.42M | 3.55M | (60.56M) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":42.17,"profit":true},{"date":"2023-12-31","value":-719.56,"profit":false}] | ||
Income Taxes | (236.56K) | (570.00) | (203.00K) | [{"date":"2021-12-31","value":-23655800,"profit":false},{"date":"2022-12-31","value":-57000,"profit":false},{"date":"2023-12-31","value":-20300000,"profit":false}] | ||
Income After Taxes | - | 3.55M | (60.36M) | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1700.43,"profit":false}] | ||
Income From Continuous Operations | - | (27.33M) | (60.56M) | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-2733300000,"profit":false},{"date":"2023-12-31","value":-6056300000,"profit":false}] | ||
Income From Discontinued Operations | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Net Income | 8.42M | 3.55M | (60.36M) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":42.17,"profit":true},{"date":"2023-12-31","value":-717.14,"profit":false}] | ||
EPS (Diluted) | 0.40 | 0.25 | (4.44) | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":62.91,"profit":true},{"date":"2023-12-31","value":-1116.68,"profit":false}] | ||
These ratios help you determine the liquidity of the company. Higher is better.
ZURA | |
---|---|
Cash Ratio | 10.32 |
Current Ratio | 10.36 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ZURA | |
---|---|
ROA (LTM) | -21.40% |
ROE (LTM) | -36.85% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ZURA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.10 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.81 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ZURA | |
---|---|
Trailing PE | 7.95 |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 1.19 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Zura Bio Limited Class A Ordinary Shares (ZURA) share price today is $2.51
Yes, Indians can buy shares of Zura Bio Limited Class A Ordinary Shares (ZURA) on Vested. To buy Zura Bio Limited Class A Ordinary Shares from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ZURA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Zura Bio Limited Class A Ordinary Shares (ZURA) via the Vested app. You can start investing in Zura Bio Limited Class A Ordinary Shares (ZURA) with a minimum investment of $1.
You can invest in shares of Zura Bio Limited Class A Ordinary Shares (ZURA) via Vested in three simple steps:
The 52-week high price of Zura Bio Limited Class A Ordinary Shares (ZURA) is $6.35. The 52-week low price of Zura Bio Limited Class A Ordinary Shares (ZURA) is $2.
The price-to-earnings (P/E) ratio of Zura Bio Limited Class A Ordinary Shares (ZURA) is 7.9474
The price-to-book (P/B) ratio of Zura Bio Limited Class A Ordinary Shares (ZURA) is 1.19
The dividend yield of Zura Bio Limited Class A Ordinary Shares (ZURA) is 0.00%
The market capitalization of Zura Bio Limited Class A Ordinary Shares (ZURA) is $295.78M
The stock symbol (or ticker) of Zura Bio Limited Class A Ordinary Shares is ZURA